ABCSG 50 / BRCA-P Summary

A randomized, double-blind, placebo-controlled, multi-center, international phase 3 study to determine the preventive effect of denosumab on breast cancer in women carrying a BRCA1 germline mutation.

Start:	07/2019
Coordinating Investigator:	Singer, Christian; Vienna
Sample size:	2.918 (international)
Design: (Click to enlarge)

Share on